Dexcom (DXCM) stock
Last close $79.32 on 2026-11-20 (-1.08%) · Sector: Healthcare
Dexcom makes continuous glucose monitors, small sensors worn on the skin that check blood sugar throughout the day so people with diabetes and their doctors can manage the condition. The company earns money mainly by selling those sensors and their related supplies.
Dexcom's business looks healthy. Revenue grew 12.8% over the past year and its balance sheet carries no long-term debt. The stock has returned 31.7% over the past year versus 4.7% for the S&P 500, though it sits 14.3% below its 52-week high. Insiders sold about $2.1 million of stock over the last 90 days and made no purchases, and the stock rose the day after all five recent earnings reports.
Key numbers
- Market cap: $30.4B
- Revenue (last 12 months): $5.10B
- Revenue growth: +12.8%
- Gross margin: 63.4%
- Operating margin: 24.1%
- P/E: 31.2
- P/S: 6.0
- Debt to equity: 0.00
- Current ratio: 1.74
Quality score
Overall 48/100 · growth 40 · profitability 49 · financial health 74 · value 29
Performance and risk
1-year return +31.7% vs S&P 500 +4.7% · volatility 37.8% (S&P 500 14.3%) · largest drop -22.6% · beta 0.70
Stock move the day after earnings
- 2026-01-12: +5.3%
- 2026-02-12: +7.6%
- 2026-04-30: +3.0%
- 2026-07-30: +12.0%
- 2026-10-29: +3.0%
Insider trades (12 months)
Bought $0.0M · sold $12.5M
DXCM stock research · DXCM options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.